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ABSTRACT
Despite the high cure rates in childhood acute lymphoblastic leukemia (ALL), 
relapsed ALL remains a significant clinical problem. Genetic heterogeneity does not 
adequately explain variations in response to therapy. The chemoprotective tumor 
microenvironment may additionally contribute to disease recurrence. This study 
identifies metabolic reprogramming of leukemic cells by bone marrow stromal cells 
(BMSC) as a putative mechanism of drug resistance. In a BMSC-extracellular matrix 
culture model, BMSC produced chemoprotective soluble factors and facilitated the 
emergence of a reversible multidrug resistant phenotype in ALL cells. BMSC environment 
induced a mitochondrial calcium influx leading to increased reactive oxygen species 
(ROS) levels in ALL cells. In response to this oxidative stress, drug resistant cells 
underwent a redox adaptation process, characterized by a decrease in ROS levels and 
mitochondrial membrane potential with an upregulation of antioxidant production and 
MCL-1 expression. Similar expanded subpopulations of low ROS expressing and drug 
resistant cells were identified in pre-treatment bone marrow samples from ALL patients 
with slower response to therapy. This suggests that the bone marrow microenvironment 
induces a redox adaptation in ALL subclones that protects against cytotoxic stress 
and potentially gives rise to minimal residual disease. Targeting metabolic remodeling 
by inhibiting antioxidant production and antiapoptosis was able to overcome drug 
resistance. Thus metabolic plasticity in leukemic cell response to environmental factors 
contributes to chemoresistance and disease recurrence. Adjunctive strategies targeting 
such processes have the potential to overcome therapeutic failure in ALL.
INTRODUCTION
Modern chemotherapeutic regimens use ten or more 
different drugs over a 2–3 year period to treat childhood 
ALL. Though recurrences are now fewer, relapsed ALL 
remains the fifth most common malignancy in children [1]. 
The complex chemotherapy schedules and the underlying 
genetic heterogeneity of the disease have made it 
difficult to understand the biological mechanisms for the 
variations in response to therapy, and relapses occurs in 
all cytogenetic subtypes. Within all genetic subtypes of 
ALL, the most sensitive predictive factor of outcome 
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is the level of minimal residual disease (MRD) in bone 
marrow aspirates at the end of the first month of therapy. 
Patients with high MRD levels have an increased risk 
of relapse [2]. This suggests that MRD represents drug 
resistant subclones selected by specific chemotherapy 
schedules; MRD cells survive and proliferate over 
time giving rise to recurrence. We recently reported 
the superiority of mitoxantrone over idarubicin, in the 
context of a randomised clinical trial in patients with 
relapsed ALL [3]. Both drugs were administered on the 
first two days of therapy but MRD levels after 4 weeks 
treatment were comparable in both arms, indicating that 
intrinsic drug resistance to idarubicin was not causal to 
outcome. However, patients treated with mitoxantrone 
experienced a higher degree of myelosupression for up to 
12 months after administration, suggesting that therapeutic 
benefit was related to an increased toxicity to the bone 
marrow, indicating the role of environment mediated drug 
resistance (EMDR) in tumor treatment failure [4, 5].
The abnormal tumor microenvironment induces a 
collection of cellular stress responses and plays a major roles 
in determining the metabolic status and chemosensitivity 
in cancer cells [6]. BMSC protect cancer cells from 
chemotherapy by activating pro-survival signal pathways 
such as PI-3K/AKT [7–9]; or releasing chemoprotective 
factors such as asparagine [10], fatty acids [11] or cysteine 
[12]. Whether BMSC mediated chemoprotection facilitates 
the emergence of drug resistant subpopulations leading 
to the development of MRD; and if such cells are able 
to persist over the long duration of ALL therapy remains 
unknown. The diverse mechanisms identified for BMSC 
mediated drug resistance also suggest that targeting specific 
signalling molecules may not be sufficient to overcome 
BMSC mediated multidrug resistance, and common 
downstream survival mechanisms need to be identified.
Oncogenic signalling pathways converge to adaptive 
cancer cell metabolisms in order to support survival. 
Targeting these unique biochemical alterations in cancer 
cells as a potential therapeutic approach is yet to be fully 
exploited [6, 13]. Cancer cells have altered redox status 
[6, 13–15] and the modifications in the levels of ROS have 
been linked to radioresistance of cancer stem cells [15]. 
In this study we show that BMSC mediated multidrug 
resistance may occur through redox adaptation in ALL 
cells. By targeting antioxidant and anti-apoptotic capacity 
in leukemic cells, we identify a potential strategy to 
overcome therapeutic failure in ALL.
RESULTS
Soluble factors produced by BMSC induce a 
multidrug resistant phenotype in ALL cells
Co-culture of ALL cells with BMSC promote 
survival, growth [16], and modulate the in vitro response 
to chemotherapy [17]. Such 2-D co-culture systems 
are being used to test efficacy of new drugs [18] and 
providing insights into the mechanisms of EMDR [19]. 
BMSC however exist in a complex 3-D milieu along with 
various types of extracellular matrix (ECM) [20, 21], and 
3-D in vitro BMSC culture systems created on artificial or 
natural scaffolds have provided differential insights in the 
mechanisms of hematopoiesis and oncogenesis [22, 23]. 
We selected a BMSC-ECM culture model, by growing 
BMSC on a biological and physiologically relevant ECM 
scaffold [24] (Supplementary Figure S1A). Briefly, BMSC 
were cultured on the plate till confluent, treated with Triton 
X-100 and NH4OH, washed with PBS to remove cellular 
components, only ECM remained on the plate. The ECM 
scaffold was produced by BMSC, contained fibronectin and 
collagen I (Figure 1A), and facilitated BMSC differentiation 
into osteoblast-like cells (Figure 1B, 1C). The BMSC-ECM 
culture model contained key bone marrow components 
including ECM, BMSC, osteoblast-like cells, and factors 
released by BMSC and osteoblast-like cells.
In vitro BMSC mediated chemoprotection has been 
investigated by incubating cancer cells in BMSC derived 
conditioned medium (CM), or co-culturing cancer cells 
with BMSC, and then treating with drugs for 3 or 4 days 
[17, 19]. In the BMSC-ECM culture model, leukemia 
cells lines incubated in CM or long term co-cultured with 
BMSC (LTCC) showed a multi-drug resistant phenotype 
(Supplementary Figure S1B, S1C, S1D), a phenomenon 
also demonstrated by primary ALL cells (Figure 1D).
To mimic the effect of chemotherapy within the bone 
marrow microenvironment, ALL cell lines SupB15, REH, 
MV4:11 and Jurkat; acute myeloid leukemia cell line U937 
and acute promyelocytic leukemia cell line NB4 cells were 
incubated in human BMSC cell line HS-5 derived CM, 
treated with 10 nM of mitoxantrone (Mito) for 6 days and then 
maintained in drug-free medium for 3 months. Control cells 
were incubated in normal medium and treated identically. 
This dose of drug was wholly lethal to cell in normal 
medium, but a population of leukemia cells incubated in CM 
survived the treatment and gave rise to multidrug resistant 
(MR) subpopulation. Similar MR cells were generated 
from SupB15 cells treated with doxorubicin (SupB15MR-D) 
(Figure 1E, 1F). BMSC releases small molecular weight 
chemoprotective molecules such as fatty acids [11] or 
cysteine [12]. Our results showed that both the <3kDa and 
≥3kDa fraction of the CM are chemoprotective. On heating 
or after proteinase K treatment, CM continued to preserve 
its chemoprotective effects (Supplementary Figure S1E). 
However, neither the <3kDa nor the ≥3kDa fractions could 
generate MR clones from ALL cells lines (Supplementary 
Figure S1F), suggesting that the MR phenotype occurred as a 
result of multiple soluble factors present in CM.
SupB15MR cells show partial restoration of 
chemosensitivity after 8 months of continuous culture in 
drug free medium (Figure 1G), indicated an epigenetic 
mechanism, previously described in drug resistant cell lines 
[25]. To further investigate the origin of the MR clones, 
Oncotarget43050www.impactjournals.com/oncotarget
SupB15, REH, MV4:11, or Jurkat cells were incubated in 
normal culture medium in the presence of 0.5 nM of MITO 
for 2 weeks and then with gradual increases in the Mito 
dose every 2–3 weeks. Cell viability was continuously 
monitored for 3 months. As shown in Figure 1H, drug 
resistant subclones were only generated from Jurkat cells. 
While SupB15, REH and MV4:11 cells survived treatment 
with 2 nM or 4 nM of Mito for a short time, they finally died 
out within 2–3 months. These results showed that BMSC 
protected ALL cells from chemotherapy in a cell type and 
drug-independent manner. This chemoprotection facilitated 
the emergence of reversible multidrug resistant subclones, 
which were more likely to be epigenetically derived [25].
BMSC induces adaptation in ALL cells 
characterized by decreased pAKT and ROS 
levels and upregulation of MCL-1
In this study, BMSC mediated short-term (CM 
protected leukemia cells from 3–4 days’ treatment) and 
long-term (CM help to generate drug resistant subclones) 
drug resistance. To investigate the mechanism underlying 
Figure 1: Generation of multidrug resistant subpopulations from ALL cell lines in a BMSC-ECM culture model. A. BMSC-
ECM scaffolds were generated from HS5, hTRET-BMSC, and primary BMSC from ALL patients (as BMSC1, 2, and 3); Immunoblots show 
the protein extracts from the ECM express fibronectin and collagen 1. β-Actin as loading control. B. Primary BMSC cultured on the BMSC-
ECM scaffold showed filamentous spindle shaped morphology and alkaline phosphatase (ALP) positive staining (after 14 days culture). BMSC 
cells cultured in plate were set as control. Microscopy was performed with a Nikon TS100 Inverted Microscope at x20 magnification. C. When 
cultured on BMSC-ECM scaffold (ECM), primary BMSC have increased expression of osteopontin (OPN) compared to cells cultured on plate 
(BMSC-plate). β-Actin as loading control. D. BMSC derived CM protected primary ALL blasts from chemotherapy. Primary ALL blasts from 
4 ALL patients were cultured in normal medium or CM, treated with doxorubicin (Doxo, 50 nM) or mitoxantrone (Mito 10 nM) for 3 days, cell 
survival were assessed by MTS assay. E. SupB15 and SupB15MR cells were treated with idarubicin (Ida, 100 nM), Mito (10 nM), clofarabine 
(Clo, 300 nM), Doxo (50 nM) for 3 days. Cell survival was assessed by MTS assay. F. JurkatMR, MV4:11MR, SupB15MR-D, U937MR, NB4MR 
and their drug sensitive parent cells were treated with Mito (10 nM) for 3 days. Cell viability was assessed by trypan blue exclusion assay. G. 
Cell viability of SupB15 or SupB15MR cells after treatment with increasing concentrations of Mito for 3 days. SupB15MR cells which had been 
continuously cultured in drug-free medium for 8 or 12 months showed decreased drug resistant capacity. H. Jurkat, MV4:11, REH and SupB15 
cells were incubated in normal medium and treated with stepwise dose increases in Mito (starting at 0.5–1 nM concentrations). Drug dose was 
increased when cells were observed to grow satisfactorily at a given dose level. At 3 months, only Jurkat cells survived the 10 nM of Mito; the 
other cell lines did not survive beyond 3 months at the indicated Mito doses. ‘X’, cell death. Data are mean ± SEM of at least three independent 
experiments (E,F). Non-parametric Mann-Whitney test (D) and unpaired 2-tailed Student’s t test (E,F). *p < 0.05, ***p < 0.001.
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BMSC induced drug resistance, we first used SILAC-
based phosphoproteomics to investigating the changing 
of signalling pathway activity in short-term (30 minutes 
and 2 hours) CM-exposed SupB15 cells (Supplementary 
Figure S2A). 1295 differentially phosphorylated peptides, 
attributable to 720 known proteins were identified after 
2 hours’ exposure to CM (Supplementary Table S1). 
Ingenuity pathway analysis (www.qiagen.com/ingenuity) 
identified activation of PI3K/AKT, MAPK and ROS 
pathways in SupB15 cells among others (Figure 2A 
and Supplementary Figure S2B). Chemosensitivity 
could be restored on prior exposure to PI3K inhibitors 
(Supplementary Figure S2C), suggesting that an alteration 
in PI3K signalling was contributory to the short term drug 
resistant phenotype.
Comparative gene expression analysis were 
performed on normal cultured SupB15; SupB15MR; and 
SupB15 cells incubated in CM for different times (from 
30 minutes to 6 days) (Figure 2B). Functional annotation 
and gene set enrichment analysis of the 6,357 genes 
differentially expressed between normal cultured SupB15 
and the other treatment groups, revealed significant 
association with regulation of ROS, PI3K-AKT, MAPK, 
apoptosis and cell cycle checkpoint pathways (Figure 2C 
and Supplementary Figure S2D, S2E; Supplementary 
Table S2 and S3). Based on this functional information, 
a heatmap with the representative gene set (2489 genes) 
confirmed the distinct contrast in gene expression 
signature between MR clones and their corresponding 
wild type control (Supplementary Figure S2F). Principal 
component analysis identified two distinct clusters with 
similarity between SupB15MR and SupB15 cells exposed 
to CM for 3 or 6 days (Supplementary Figure S2G). This 
suggested a temporal switch in drug resistant pathways 
between 3–6 days of exposure to CM. Verification of the 
identified pathways using Western blot showed that drug 
resistant cells, including MR cells, SupB15 cells incubated 
in CM for 3 days, and SupB15LTCC cells, had increased 
expression of antioxidants (MnSOD2, GPX1/2), anti-
apoptotoic protein MCL-1, and decreased AKT ser473 
phosphorylation when compared to cells grown in normal 
medium (Figure 2D). Low pAKT was also detected in 
JurkatMR and MV4:11MR cells (Figure 2E).
Time course experiments were performed to 
investigate the effects of CM on AKT activity in ALL 
cells. As shown in Figure 2F, AKT activity in SupB15 cells 
fluctuated according to incubation time. After exposure to 
CM, AKT ser-473 phosphorylation increased at 2–8 hours 
with a subsequent decline from 24 hours to a steady level 
at 72 hours. Intracellular ROS level in ALL cells showed 
similar fluctuations after exposure to CM. In SupB15 cells, 
ROS levels and mitochondrial membrane potential (Δψm) 
increased from 0.5 hours, peaked at 4 hours, and decreased 
to lower than basal levels at 72 hours (Figure 2G). In 
primary ALL blasts, ROS levels increased after 2 hours’ 
exposure to CM, but decreased after 24 hours (Figure 2H). 
MR cells too have lower intracellular ROS levels and Δψm 
when compared with their drug sensitive parent cells 
(Supplementary Figure S2H, S2I).
BMSC induced chemoresistance is distinct from 
its effect on cellular proliferation
Constitutive activation of the PI3K/AKT pathway 
promotes cancer cell proliferation [26–29]. The low AKT 
activity mediated by BMSC in ALL cells was associated 
with decreased cellular proliferation (Figure 3A) and 
cell cycle progression (Figure 3B), and increased p27 
expression (Figure 3C) in vitro. Comparing with SupB15 
cells, SupB15MR showed delayed engraftment kinetics in 
NOD-scid IL2Rgammanull (NSG) mice (Figure 3D). This is 
consistent with evidence that BMSC inhibit proliferation 
and function of immune cells [30, 31], as ALL cells are 
malignant counterparts of immature lymphocytes.
To assess the association between BMSC mediated 
growth suppression and chemoprotection, SupB15 cells 
were stably transduced with p27shRNA (SupB15p27kd) or 
vector control (SupB15vector), incubated in CM or normal 
medium and treated with doxorubicin for 3 days. Unlike that 
observed from SupB15vector cells, SupB15p27kd cells grew at a 
similar rate when cultured in CM or normal medium (Figure 
3C, lower panel; and 3E). Nevertheless, CM was equally 
protective of SupB15p27kd or SupB15vector cells against 
doxorubicin (Supplementary Figure S3A). When incubated 
in CM, SupB15 cells have high AKT activity at 2 hours and 
low AKT phosphorylation after 24 hours (Figure 2F). The 
proportion of cells at G1 phase was increased significantly 
after 24 hours incubation (Figure 3B). 10 nM of Mito was 
added into culture at these two time points (2 hours and 24 
hours after incubation in CM). After 3 days’ treatment, cell 
survivals in these two groups were similar (Supplementary 
Figure S3B). These results suggested that BMSC-ECM 
mediated chemoprotection is not regulated by alterations in 
cellular proliferation.
BMSC regulates intracellular ROS level and 
induce redox adaptation in ALL cells
Compared with cells in normal medium, medium 
containing 25% CM (v/v) also increased ROS levels 
(Figure 4A), suggesting that the increased ROS production 
in ALL cells was not due to the lack of nutrients in CM. 
ROS generating enzymes are activated by increased 
mitochondrial calcium (mCa2+) concentrations [32]. To 
examine whether BMSC regulation of ROS metabolism 
was related to mCa2+ influx, SupB15 cells were incubated 
in CM and mCa2+ concentrations were assessed by 
Rhod-2 staining followed with flow cytometry analysis. 
mCa2+ concentrations increased after 30 minutes, and 
gradually decreased from 2 hours returning to basal levels 
after 24 hours. Intracellular ROS levels paralleled the 
temporal changes in mCa2+ concentrations (Figure 4B). 
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The fluctuations of mitochondrial calcium influx were 
unrelated to intercellular Ca2+ concentrations as they 
were similar in both CM (30.6 ± 2.42mg/L) and normal 
medium (30.8 ± 0.8mg/L). RU360, a selective inhibitor 
of mitochondrial calcium uptake, suppressed CM induced 
ROS generation (Figure 4C). As RU360 is unstable in the 
presence of oxygen, the calcium chelator BAPTA-AM 
was used to test the role of mCa2+ influx in CM induced 
drug resistance. CM failed to stimulate ROS generation 
(Figure 4D) or provide chemoprotection in BAPTA-AM 
pre-treated ALL cells (Figure 4E).
We have shown that BMSC-CM dynamically 
regulated ROS levels in ALL cells and resulted in a low 
intracellular ROS status. The decreased ROS levels in 
ALL cells after incubation in CM was not the consequence 
of CM mediated growth inhibition, as SupB15p27kd cells 
have the same proliferation rate when cultured in normal 
or CM, but ROS levels decreased after incubation in 
CM for 72 h (Supplementary Figure S4). These findings 
suggested that the BMSC microenvironment induced a 
redox adaptation in ALL cells. To address this hypothesis, 
NSG mice were engrafted intrafemorally with 1 × 105 of 
Figure 2: Multidrug resistant cells have lower intracellular ROS levels and AKT activity. A. Ingenuity pathway analysis 
of phosphoproteomic data show signal pathways activated in SupB15 cells after exposure to HS-5 derived CM for 2 hours. B. Gene 
expression profiles of SupB15, SupB15 incubated in CM for different times, and two SupB15MR clones (MR1 and MR2). Data were 
analysed by GeneSpring GX software (Agilent Technologies, Inc.). C. GSEA plot showing differential expression of ROS related genes in 
SupB15 and SupB15MR cells. GSEA plots of gene expression related to AKT, apoptosis, chromatin remodeling, DNA repair, and ATPase 
are shown in Supplementary Figure S2D. D. Compared with SupB15 cells incubated in normal medium (ctr), SupB15 cells cultured in 
CM for 3 days, SupB15LTCC and SupB15MR show increased expression of PTEN, Glutathione peroxidase (GPX 1/2), MnSOD2 and MCL-1; 
decreased expression of ser473-AKT phosphorylation (pAKT), and relative unchanged expression of BCL-2 and BCL2L1. E. MR cells 
have decreased pAKT compared to their drug sensitive parent cells. All cells were maintained in normal medium. F. Immunoblot showing 
temporal biphasic expression of pAKT in SupB15 cells incubated in CM. Following an initial increase (2–8 hours incubation), pAKT 
expression declines (24–48 hours incubation), then stabilizes to a lowered steady state at 72 hours. G. ROS level (DCF-DA), Superoxide 
level (Dihydroethidium, dHE), and Δψm (CMXRos) in SupB15 cells when incubated in CM for 0.5 to 72 hours, cells incubated in normal 
medium as time ‘0′. H. ROS levels increased in primary ALL blasts after incubated in medium containing 50% of CM (v/v) for 4 hours 
(n = 2, histogram); and decreased after 24 hours’ incubation (n = 6, box plot). Cells incubated in normal medium as control (ctl). Data are 
mean ± SEM of at least three independent experiments. Non-parametric Mann-Whitney test (H) **p < 0.01.
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SupB15LucGFP cells and treated with methotrexate (5 mg/kg) 
or saline from day 8 (Figure 4F). Compared with in vitro 
cultured cells, SupB15LucGFP cells obtained from femoral 
flushes of both treated and untreated mice showed higher 
expression of GPX1/2, MnSOD2 and MCL-1 (Figure 
4G), lower levels of ROS and Δψm, and higher levels of 
GSH (Figure 4H). Together, BMSC microenvironment 
induces an initial increase in intracellular ROS levels and 
Δψm via an influx of calcium ions into mitochondria. As 
excess ROS is harmful to cells, ALL cells adapt to this 
oxidative stress by increasing antioxidant production and 
lowering intracellular ROS levels. This redox-adapted 
phenotype is maintained by cells surviving post exposure 
to chemotherapy, as illustrated by MR cells.
Low ROS levels characterize subpopulations 
of primary ALL cells with relative resistance to 
chemotherapy
Both long term CM-exposed ALL cells and MR cells 
had low ROS levels. We proposed that ROSlow subpopulations 
of CM-exposed ALL cells were likely to be more resistant 
to chemotherapy than ROShigh subpopulations. To test this, 
SupB15 cells were incubated in CM for 6 days and sorted into 
ROSlow and ROShigh populations (<10% of whole population) 
using DCF-DA staining. ROSlow cells were relative resistant to 
chemotherapy with Mito or Doxo when compared to ROShigh 
cells on (Figure 5A). Next we examined the chemosensitivity 
of the subpopulations in primary ALL blasts with differential 
Figure 3: BMSC induced chemoresistance is distinct from its effect on cellular proliferation. A. SupB15 and SupB15MR 
cells were cultured in normal medium; or SupB15 cells were maintained in medium containing 50% of CM (v/v) for 4 days. Cell number 
were normalised to day 1. Cell proliferation was assessed with MTS assay. B. Cell cycle progression in SupB15 cells when cultured 
in CM. After 24 to 72 hours, cells showed a higher proportion of cells in G1 phase, lower proportion of cells in S and G2/M phase. 
C. After incubation in CM for 24 to 72 hours, SupB15 cells showed increased expression of p27, decreased expression of p21, the 
expression of p53 did not change (upper panel). CM failed to upregulate p27 expression in SupB15p27KD cells (lower panel) after 24 or 
48 hours’ incubation. D. 1 × 105 of SupB15LucGFP or SupB15MRLucGFP cells were injected into NSG mice (n = 6 each group) intravenously. 
Representative images of 3 mice from a cohort of 6 animals showing delayed engraftment kinetics of SupB15MR transplanted mice when 
comparing with SupB15 cells. Leukemia engraftment was measured with bioluminescence. E. SupB15 cells with p27 wild type (vector) 
or knockdown (p27KD) were incubated in normal medium or CM. CM equally protected SupB15vector and SupB15p27kd cells from Doxo 
(50 nM, 72 hours) treatment. Data are mean ± SEM of at least three independent experiments (A,B,E). unpaired 2-tailed Student’s t test 
(A, E). **p < 0.01, ***p < 0.001.
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intracellular ROS levels. CD19+ primary ALL blast cells, 
obtained from diagnostic bone marrow aspirates could be 
characterized into 3 subpopulations based on ROS levels, 
low, medium and high. After exposure to CM for 24 hours, 
there was a moderate expansion in the ROSlow subpopulation 
(Figure 5B). We engrafted primary ALL cells intrafemorally 
in non-irradiated NSG mice. Femoral flushes were obtained 
on evidence of engraftment and purified CD19+ ALL blasts 
were sorted into ROSlow and ROShigh populations, treated with 
Mito or Doxo for 3 days. ROSlow cells were again shown 
to be comparatively more drug resistant than ROShigh cells 
(Figure 5C).
Inhibiting antioxidants and antiapoptotic capacity 
overcomes BMSC mediated drug resistance
As shown earlier, the drug resistant phenotype was 
further characterized by upregulation of the antiapoptotic 
BCL2 family members BCL-2, BCL2L1 and MCL-1. 
Overexpression of MCL-1 has been previously associated 
with drug resistance in cancer [33–35]. MCL-1 was 
upregulated in LTCC, CM exposed ALL cells, MR cells 
(Figure 2D), and bone marrow engrafted primary ALL cells 
(Figure 4G). Transient MCL-1 knockdown by siRNA, or 
the MCL-1 inhibitor Obatoclax sensitized SupB15 and 
SupB15MR cells to H2O2 cytotoxicity (Figures 6A, 6B, 
and Supplementary Figure S5), suggesting that MCL-1 
contributes to the redox adaptation process in ALL.
Under oxidative stress, cancer cells increase 
their antioxidant capacity and develop a drug resistant 
phenotype. Targeting this redox adaptation process has 
significant therapeutic implications [13]. Piperlongumine 
(PL) [36, 37], β-phenethyl isothiocyanate (PEITC) [38] 
and Adaphostin (Ada) [39] have dual effects of increasing 
ROS production and suppressing BCL-2 family molecules. 
10 μM of PEITC, PL, or Ada strongly stimulated ROS 
generation (Figure 6C) and were lethal to SupB15MR, 
SupB15LTCC and SupB15CM cells (Figure 6D, 6E and 6F). 
Figure 4: BMSC regulates intracellular ROS levels and induce redox adaptation in ALL cells. A. Medium containing 
different proportion of CM (25%, 50% or 75%, v/v) increased ROS production in REH cells after 4 hours’ incubation. B. Level of ROS 
(DCF-DA) and mitochondrial calcium (Rhod-2) in SupB15 cells after incubation in CM for indicated times. C. SupB15 cells were 
treated with RU360 (10 μM) for 1 hour, then incubated in CM for 2 hours. CM failed to increase ROS level. D. and E. Pre-treatment 
of SupB15 cells with BAPTA-AM (3 μM, 2 hours) inhibited (D) CM induced ROS generation and (E) CM mediated chemoprotection. 
F. and G. Intrafemorally engrafted SupB15LucGFP cells showed increased expression of GPX1/2, MnSOD2, and MCL-1 when compared to 
SupB15LucGFP cells cultured in vitro. H. Intrafemorally engrafted SupB15LucGFP cells had lower levels of ROS and Δψm; higher level of GSH 
when compared to in vitro cultured cells. n = 6 mice per group. Data are mean ± SEM of at least three independent experiments (C,D,E). 
Non-parametric Mann-Whitney test (H) and unpaired 2-tailed Student’s t test (C,D,E). **p < 0.01, ***p < 0.001.
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The ROS scavenger N-acetyl-cysteine (NAC) reversed 
the effects of PEITC or PL, but was less effective against 
Ada. This may due to the fact that Ada inhibits ABL1 
kinase activity and SupB15, while highly chemosensitive, 
is a BCR-ABL positive cell line. All three drugs strongly 
induced γ-H2AX phosphorylation and inhibited MCL-1 
(not BCL-2 or BCL2L1) expression (Figure 6G and 
6H). Therefore the simultaneous increase of ROS and 
inhibition of MCL-1 appeared to inhibit BMSC induced 
chemoprotection.
Targeting antioxidants and MCL-1 effectively 
against ASNase resistance in primary ALL blasts
We next evaluated the role of antioxidant and MCL-
1 targeting as adjunct strategies in ALL therapy. The 
anticancer effects of PEITC are dose-dependent. Compared 
to SupB15 cells, SupB15MR were sensitive to 10 μM of 
PEITC but more resistant to 2 μM of PEITC (Figure 7A). 
Serum concentrations of PEITC reached ~1 μM after oral 
intake [40], posing a practical hurdle for its clinical use. 
Figure 5: Low ROS levels characterized subpopulations of primary ALL cells with relative resistance to 
chemotherapy. A. Roslow SupB15 cells were relatively drug resistant than that of Roshigh cells after treated with Mito (10 nM) or Doxo 
(50 nM) for 72 hours. B. Flow cytometry dot plots (side scatter SSC vs DCF-DA staining) indicated presence of distinct ROShigh, ROSintermediate 
and ROSlow subpopulations in CD19 positive primary ALL cells (ALL1, ALL2, ALL3). The ROSlow subpopulation expanded on 24-hours 
incubation with CM. Lymphoprep™ density gradient centrifugation were used to exclude dead cells. After 24 hours’ incubation in normal 
medium or CM, cell viability were more than 90% (Trypan blue exclusive assay), and cells incubated in CM had better viability than 
cells incubated in normal medium. Dead cells were further excluded by SSC/FSC gating on Flowjo software. C. ROSlow populations of 
primagraft ALL blasts were more drug resistant than that of ROShigh cells (n = 5). CD19 positive primagraft cells were collected from mice 
bone marrow flushes, purified with magnetic purification, and dead cells were excluded by Lymphoprep™ density gradient centrifugation. 
Cells were sorted into ROSlow and ROShigh cells based on intracellular ROS level (DCF-DA staining). In the process of cell sorting, dead/
dying cells were excluded by SSC/FSC gating and propidium iodid (PI) staining. Cells were then incubated in medium containing 50% 
CM (CM), and treated with Mito (15 nM) for 72 hours. Data are mean ± SEM of at least three independent experiments. unpaired 2-tailed 
Student’s t test (A) and Non-parametric Mann-Whitney test (C) *p < 0.05, ***p < 0.001.
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GSH is the main cellular antioxidant. A potential strategy 
would be to combine PEITC with reagents that inhibit 
GSH synthesis, such as buthionine sulfoximine (BSO) 
or the anti-leukemic drug L-Asparaginase (ASNase). 
ASNase converts asparagine to aspartate and glutamine to 
glutamate. The depletion of both asparagine and glutamine 
by ASNase appears to be required for its cytotoxic action 
[41], and ASNase has been reported to deplete serum 
glutamine and suppresses GSH levels in ALL patients [42]. 
We speculated that the effect of ASNase could in part be 
related to its antioxidant activity and used in combination 
with PEITC could potentiate its effect. REH and SupB15MR 
cells are highly resistant to ASNase when compared to 
SupB15 (Figure 7B). The combinations of PEITC with 
BSO or ASNase were more effective in suppressing 
MCL-1 activity, stimulating γ-H2AX expression 
(Figure 7C), inhibiting GSH expression (Figure 7D) and 
increasing ROS levels (Figure 7E) in SupB15MR and REH 
cells, than PEITC or ASNase alone. PEITC potentiates 
ASNase cytotoxicity in SupB15MR and REH cells (Figure 
7F and 7G).
As shown earlier, in patients with ALL, BMSC 
microenvironment mediated redox adaptation has occurred 
in a proportion of leukemic cells prior to treatment. We 
speculated that these cells persist after initial therapy. 
Sufficiently expanded, these cells may give rise to detectable 
MRD. Primary diagnostic blasts obtained from MRDlow (<10–
4) and MRDhigh (≥10–4) patients recruited to the UKALL2003 
clinical study [43] were analyzed (Supplementary Figure 
S6A). These patients were treated with a 3-drug induction 
of dexamethasone, vincristine and ASNase. 28 days after 
starting therapy, MRD assessments were performed. 
Trough ASNase activity was measured at two time 
points during induction (Supplementary Figure S6B). 
Figure 6: Inhibiting antioxidants and antiapoptotic capacity overcome BMSC mediated drug resistance. A. and B. 
Suppression of MCL-1 expression sensitizes SupB15 cells to H2O2 treatment. SupB15 cells were (A) transfected with MCL-1 siRNA (1 μM) 
for 72 hours; or (B) treated with Obatoclax (100 nM) for 24 hours. Cells were then treated with H2O2 (80 μM) for 24 hours. Cell viability 
was assessed by trypan blue exclusion assay. C. PEITC (5 μM), PL (10 μM), or Ada (5 μM) stimulated ROS production in SupB15MR cells 
after 1 hour treatment. Effects were reversed by NAC (3 mM, 2 hours) pretreatment. D, E. and F. PEITC (D), PL (E) and Ada (F) were 
toxic for SupB15 in normal medium (as control); SupB15 incubated in CM; SupB15LTCC; and SupB15MR cells. Note the differential effects 
of NAC (3 mM) pre-treatment on the toxicity of PEITC, PL and Ada. G. 2 hours of PEITC (5 μM), PL (10 μM), or Ada (5 μM) treatments 
inhibited MCL-1 expression, and induced γ-H2AX expression in SupB15 and SupB15MR cells. Cells were maintained in normal medium. 
H. MCL-1 expressions in cells were strongly inhibited after 2 hours of PEITC (5 μM), PL (10 μM), or Ada (5 μM) treatment: SupB15, REH 
and SD1 cells were incubated in CM for 3 days; and SupB15LTCC, REHLTCC, and SD1LTCC were cultured in normal medium. Data are mean ± 
SEM of at least three independent experiments. unpaired 2-tailed Student’s t test (A,B,C,D,E,F). **p < 0.01, ***p < 0.001.
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All patients had adequate ASNase activity at both time 
points (>100 U/L) [44], indicating adequate drug activity. As 
shown in Figure 7H, blast cells from MRDhi (n = 10) patients 
displayed proportionately increased resistance to ASNase 
when compared to cells from MRDlow patients (n = 15). This 
is indicative of an expanded drug resistant population in the 
pre-treatment bone marrow sample in the MRDhi group. 
The addition of PEITC or PL overcame ASNase resistance. 
Immunoblots showed that the combination of PEITC or PL 
with ASNase strongly inhibited MCL-1 levels and induced 
γ-H2AX expression in primary ALL blasts (Supplementary 
Figure S6C). Thus targeting antioxidants production and 
inhibiting MCL-1 may be potential adjunctive therapeutic 
strategies to overcome MRD in childhood ALL.
DISCUSSION
Analyses of the effect of the microenvironment 
created by the in vitro BMSC-ECM 3-D model offer 
possible biological explanations for the clinical variations 
in response to therapy in childhood ALL (Figure 8). As 
in most cancers, at diagnosis the majority of leukemic 
cells though metabolically active are not proliferative 
and mainly dying. Only a small populations of slowly 
cycling cells survive and give rise subsequently to fast 
cycling progenitors [45]. Our study suggests that the 
BMSC microenvironment produces an oxidative stress 
response in ALL cells. A subpopulation of ALL cells 
underwent redox adaptation, tolerated lethal doses of 
chemotherapy and gave rise to MR cells; a phenomenon 
Figure 7: Targeting antioxidants and MCL-1 effectively restored sensitivity to ASNase in ALL cells. A. Variations in cell 
viability of SupB15 and SupB15MR cells after treatment with PEITC (2 μM or 10 μM) for 24 hours. B. IC50 of ANSase in SupB15, REH, 
and SupB15MR cells. C. Combination of PEITC with ASNase strongly inhibited MCL-1 expression and increased γ-H2AX expression in 
SupB15MR and REH cells. PEITC (2 μM) for 48 hours; ASNase (ASN) for 72 hours (2 IU/ml for REH, 5 IU/ml for SupB15MR); or ASNase 
for 24 hours, then PEITC for further 48 hours (PEITC + ASN). D. and E. Combination of PEITC with ASNase (ASN) or BSO (D) inhibited 
GSH expression and (E) increased ROS generation in SupB15MR cells after 20 hours’ treatment. PEITC (2 μM); ASNase (5 IU/ml); BSO 
(100 uM). F. and G. Cell viability of SupB15MR (F) or REH (G) following treatment: PEITC (2 μM) 48 hours; ASNase 96 hours (5 IU/ml 
for SupB15MR, 2IU/ml for REH); ASNase 48 hours, then PEITC 48 hours (PEITC + ASN). H. The addition of PEITC or PL overcame 
ASNase resistance in primary ALL cells. Diagnostic blast cells from MRDhigh or MRDlow patients were incubated in medium containing 
50% CM, and treated with ASNase (2 IU/ml) for 72 hours; PEITC or PL (2 uM) for 48 hours; or ASNase for 24 hours, followed by PEITC 
or PL for further 48 hours. Data are mean ± SEM. Unpaired 2-tailed Student’s t test (A,D,E,F and G) and nonparametric Mann-Whitney test 
(H) *p < 0.05, **p < 0.01, ***p < 0.001.
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not recapitulated by cells grown in normal medium. MR 
cells are characterised by decreased proliferation and 
multidrug resistance. This result agrees with the finding 
that in childhood ALL patients after 8 days treatment, 
persisting blast cells had decreased proliferative activity 
[46]. The method of generating MR cells parallels the 
clinical setting as cancer cells were cultured in a protective 
environment and exposed to toxic drug levels. In patient, 
treated with intensive combination chemotherapy MRD of 
≥10–4 after 4 weeks of treatment is associated with a poorer 
outcome even though treatment lasts over 2-years. Further 
intensification with myelosuppressive therapy is associated 
with a clearance of MRD and better outcomes [47]. Our 
model suggests that EMDR derived, slowly proliferative, 
multidrug resistant cells survived initial cytotoxic stress 
and if sufficiently expanded were detectable as MRD. 
Cytotoxic therapy is non-specific and injurious to both 
leukemic and the protective microenvironment. This is 
one possible explanation for our observation of the clinical 
benefits of the more myelotoxic mitoxantrone when 
compared to idarubicin [3].
When removed from the stressful environment, 
MR cells gradually lose their drug resistant phenotype, 
a feature also described in other cancers [25] and 
provides a model for late relapses. ALL patients with 
late relapses occurring many months after stopping 
therapy often respond to further intensification by similar 
chemotherapeutic agents. If MRD is cleared then many 
patients can be cured second time round [47]. On the 
contrary recurrences whilst on therapy are often associated 
with rapidly progressive disease and poor outcomes even 
after allogeneic stem cell transplantation [3]. SupB15 
cells with p27 knockdown retained their drug resistant 
phenotype but were proliferative when incubated in 
BMSC CM. Similarly, mutations and deletion of the cell 
cycle control gene TP53 are associated with early highly 
aggressive relapse with poor outcomes [48].
Our experiments revealed a distinct biphasic 
response in ALL cells upon BMSC-CM stimulation, with 
initial upregulation of AKT activity and intracellular 
ROS levels, followed by decreased pAKT and ROS level 
after 24 to 72 hours, together with increased antioxidants 
Figure 8: Model of bone marrow microenvironment mediated drug resistance in ALL and its clinical correlation. The 
bone marrow microenvironment exerts oxidative stress on leukemic cells by promoting mitochondrial calcium influx, increasing intracellular 
ROS levels and Δψm, and activating AKT. In response, leukemic cells initiate a mediated redox adaptation process, resulting in an increased 
expression of antioxidants (e.g. GSH and MnSOD2) and MCL-1, decreased ROS levels, Δψm and AKT activity. This confers a multiple 
drug resistance (MR) phenotype in leukemic cells. MR cells exist at diagnosis and can be detected as MRD post therapy. Cells with 
deregulated cell cycle control give rise to early recurrence. Other drug resistant cells gradually regain a degree of chemosensitivity, and 
respond to intensification with cytotoxic drugs. Alternatively, inhibiting antioxidants and MCL-1 activity as adjunctive therapy can target 
the MR phenotype.
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expression. Short-term drug resistance, characterised by 
increased AKT activity and intracellular ROS levels, was 
reversed by pretreating cells with PI-3K/AKT inhibitor, 
as previously reported [7, 8]. Similar to the long-term 
drug resistant phenotype, leukaemia-initiating cells have 
low AKT activity [49], as do ‘stem-cell like’ cancer drug 
resistant cells [25]. So the metabolic phenotype of drug 
resistant cells observed in this study is common with 
other drug resistant cancer cells and cancer stem cells 
[15, 50–52]. The association between short- and long-
term drug resistances indicates an evolutionary process, 
as illustrated in our mechanistic model (Figure 8).
This process also leads to the upregulation of the 
mitochondrial anti-apoptotic protein MCL-1. MCL-1 is 
one of the most highly amplified genes in a broad range of 
human cancers [33, 53] and its expression rapidly changed 
in responds to cellular stresses [54]. A recent study suggested 
that outer mitochondrial membrane localized MCL-1 possess 
antiapoptotic activity, and the mitochondrial matrix localized 
MCL-1 isoform supports oxidative phosphorylation, 
ATP production, and the maintenance of mitochondrial 
membrane potential [55], so it is possible that inhibition of 
both the anti-apoptotic and the mitochondrial functions of 
MCL-1 may lead to more effective therapies. In line with 
these findings, we found that MCL-1 as the most upregulated 
anti-apoptotic molecules in cells exposed to CM. In some of 
our experiments, MCL-1 protein appeared as a doublets as 
detected by Western blot, depending on the conditions of 
SDS-PAGE. Suppression of MCL-1 expression by siRNA or 
obatoclax sensitized ALL cells to H2O2 induced cell death. 
PEITC, PL, or Adaphostin treatments effectively inhibited or 
abolished MCL-1 expression, but not that of BCL-2 or BCL-
xL. Moreover, at certain concentrations, the multiple drug 
resistant SupB15MR was more sensitive to PEITC or PL than 
its drug sensitive counterpart. Given that low MMP and high 
MCL-1 is the feature of BMSC mediated drug resistance, 
the extensive metabolic reprogramming in cancer cells may 
make them more vulnerable to motochondrial perturbations 
than normal cells [56], so it is possible that drug resistant 
cells may rely on high antioxidants and MCL-1 to maintain 
normal mitochondrial morphology. Inhibiting MCL-1 and 
antioxidants activity is able to further decrease MMP and 
eventually induce mitochondrial membrane collapse and 
cell death.
Our study has a number of limitations, chief of which 
is that the mechanisms of bone marrow microenvironment/
BMSC mediated drug resistance were mainly explored in 
leukemic cell lines and murine models. Among the multiple 
signal pathways regulated by BMSC cells, as shown in our 
phosphoproteomics and gene expression analyses, we only 
investigated PI3K/AKT, cell proliferation, anti-apoptosis, 
and ROS metabolism in ALL cells. The nature of the 
subpopulations of cells that undergo redox adaptation remains 
unclear. As MRD levels vary with cytogenetic subtypes, it 
is possible that primary and secondary genetic subclonal 
changes may facilitate the redox adaptation. Murine models 
suggest that leukemic cells persist within the marrow 
after chemotherapy [57]. However the leukemic marrow 
environment is different to that of a marrow in remission. 
We do not know if the oxidative stress and response is 
different, or with time epigenetic transfer decreases leading to 
proliferation and increased chemosensitivity in daughter cells. 
Given the complexity of EMDR, more detailed investigation 
on other signalling pathways and better animal studies are 
required. Another limitation of this study is that the role of 
the immune system has not been explored in vitro and in vivo 
experiments. Genetic and epigenetic alterations happened in 
cancer cells may provide a diverse set of antigens that could 
be served as targets for immunotherapy. For example, PD1 
pathway, an immune-checkpoint pathway that primarily 
operates in the tumour microenvironment, has emerged as a 
promising target in cancer [58].
Our study adds to the evidence that drug resistance 
in cancer cells is determined by both intrinsic and 
microenvironmental factors. Further in-depth investigation 
of metabolic profiling and epigenetic changes in the 
development of cancer drug resistance will provide 
insights into clinical treatment failure and relapse.
MATERIALS AND METHODS
Human tissue and cell lines
Clinical samples were obtained after informed signed 
consent from patients enrolled into the national clinical trial 
(ALL 2003) for children with ALL. National and Local 
ethical committees approved analyses of samples and 
ASNase activity. Primary ALL blast cells from bone marrow 
aspiration were separated with Ficoll gradient centrifugation 
(Lymphoprep; Axis-Shield). Leukemia cell lines were 
maintained in RPMI 1640 (Lonza, Belgium) supplemented 
with 10% fetal calf serum (FCS, Biosera). Primary BMSCs 
were prepared from ALL patients at diagnosis or have been 
received intensive chemotherapy. Only BMSC of three to 
six passages were used. Primary BMSC and human BMSC 
cell line HS-5 and hTRET-MSC were cultured in DMEM 
medium (Lonza) supplemented with 10% FCS, 100 U/ml 
penicillin and 100 μg/ml streptomycin. Differentiation 
of BMSC into osteoblast-like cells was assessed by alk-
aline phosphatase (ALP) staining (Roche, Germany) and 
osteopontin expression.
Animal experiments
All animal procedures were approved by the Cancer 
Research UK Manchester Institute’s Animal Ethics Committee 
and performed under a project license issued by the United 
Kingdom Home Office, in keeping with the Home Office 
Animal Scientific Procedures Act, 1986. NOD/SCID/IL-
2Rγnull (NSG) mice were purchased from Jackson Laboratories 
(Bar Harbor, ME, USA) and bred in house. To investigate bone 
marrow microenvironment mediated redox adaptation in ALL 
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cells, 1 × 105 of ALL cells were transplanted into NOD/shi-
scid/IL-2Rγnull mice femoral bone marrow. Mice were treated 
with methotrexate (5 mg/kg body weight) or PBS after 8 days 
transplantation. Bone marrow mononuclear cells were flushed 
from bone marrow after three weeks’ transplantation. Cells 
were gated with GFP (for SupB15LucGFP cells) or CD45 (for 
non-labelled cells) on flow cytometry.
Generation of BMSC derived extracellular 
matrix (ECM)
BMSC-ECM was generated by growing BMSC 
to confluence in normal medium [24]. Briefly, primary 
or cell line BMSCs were cultured in normal medium, 
just prior to reaching confluent, cells were treated with 
50 ug/ml of ascorbic acid (Sigma) and cultured for another 
5 days. BMSCs layer were treated with extraction buffer 
containing 0.5% (v/v) Triton X-100 and 20 mM NH4OH, 
gave rise to cell free ECM that remain attached to the 
culture plates. After washed three times with ice-cold PBS, 
the resulting extracted ECM can be stored at 4°C in PBS 
containing 100 U/ml penicillin and 100 ug/ml streptomycin 
with parafilm sealing for up to 3 months.
Generation of conditioned medium and 
ultrafiltration
BMSCs were cultured in complete medium on the 
BMSC-ECM layer until reach about 70% confluence, 
then serum free RPMI1640 were added and incubated 
for 24–48 hours. Cell culture supernatant were collected, 
centrifuged at 3500 rpm for 10 min to clear cells debris, 
then passed 0.2 μm filter. CM was snap frozen in dry ice, 
and kept in −80 °C. CM was diluted with normal medium 
at a ratio of 1:1 just before use. CM fractions (<3kDa 
and >3kDa) were ultra-filtrated at 3000 Da (Millipore, 
Billerica, MA, USA), 3000 × g, 60 min, at 4°C.
RNA extraction, microarray, and GSEA analysis
Total RNA were purified by Qiagen RNeasy Micro 
kit, cDNA was amplified and labelled with Nugen Ovation 
Biotin labelling system (NuGEN Technologies). Labelled 
probes were hybridized to Affymetrix U133A 2.0 PLUS 
Array. The probe-level expression values in the data obtained 
from the Affymetrix HG133plus2 array were normalised and 
summarised as the expression values at the probeset level 
using the RMA method implemented in the Affymetrix’s tool 
‘apt-probeset-summarize’. Data (.CEL files) were analyzed 
using the R statistical package bioconductor and Genespring 
7.3.1 software. Gene array data were deposited in NCBI gene 
expression database Gene Expression Ominibus (GEO), 
accession number GSE48876.
The probe set-level expression data was loaded into 
the gene set enrichment analysis (GSEA) software. We 
created six gene sets, which involved in ROS metabolism 
(68 genes), AKT pathway (64 genes), apoptosis (110 
genes), ATPase (46 genes), DNA repair (41 genes) and 
Chromatin remodelling (76 genes) by selecting genes 
from previously published gene list or the gene lists from 
SABiosciences website (http://www.sabiosciences.com/
ArrayList.php) with modification based on published 
methods, only genes with published evidence of functions 
were included in the final gene list. In the GSEA analysis, 
we used the default settings except using the ‘gene-set’ as 
the permutation type, the Chip file provided by the GSEA 
software for the Affymetrix HG133plus2 array, and the 
‘Diff_of_Classes’ option as the metric for ranking genes.
Triple SILAC based phosphoproteomics
SupB15 and HS-5 cells were grown in heavy 
(H) Arginine (13C6 
15N4 L-Arginine-HCl)/Lysine (
13C6 
15N2 L-Lysine-2HCl), intermediate (I) Arginine (
13C6 
L-Arginine-HCl)/Lysine (13C6 L-Lysine-2HCl) and light 
(L) Arginine (L-Arginine-HCl)/Lysine (L-Lysine-2HCl) 
media for a minimum of five passages according to 
manufacturer’s instructions. All media was supplemented 
with 230 μg/ml L-Proline to prevent conversion of 
Arginine to Proline. After serum starved overnight, 
SupB15 cells were treated with SILAC conditioned 
media (CM) from HS-5 cells for 30 mins or 2 hrs. Then 
cells were washed with ice-cold PBS, equal numbers 
of H, I and L viable SupB15 cells were mixed together, 
lysed with 50 mM Tris, 4% SDS containing protease and 
phosphoprotease inhibitor cocktails (Roche) on ice for 
30 mins. Protein samples were then digested with trypsin, 
desalted and dried down. Seven aliquots (each around 
320 ug) were combined. The sample was split equally 
into ten portions for TiO2 enrichment and subjected to 
a LTQ OrbitrapXL mass spectrometer (Thermo Fisher, 
Hertfordshire, UK) for analysis.
shRNA and siRNA transfection
Lentiviruses which express GFP, p27 shRNA or 
their empty vector control were produced in 293T cells, 
transfected into SupB15 cells and stable transfection 
were selected with 10 ug/ml of Puromycin. Accell 
MCL-1 siRNA or its control siRNA (Thermo Scientific 
Dharmacon) were transduced into ALL cell lines according 
to manufacturer’s instruction. 3 days after transfection, 
protein knockdown were assessed by Western Blot and 
cells were immediately used for experiments.
Cell proliferation and viability
Cell proliferation and viability was analyzed by 
using CellTiter96Aqueous One Solution Cell proliferation 
Assay kit (Promega, Madision, WI, USA) according to the 
manufacturer’s protocol. Cell viability was determined 
by recording the absorbance at 490 nM using a 96-well 
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plate reader (FLUOstar Omega). Cell viability was also 
be determined by Trypan blue exclusion (Invitrogen) assay 
and the cell viability were assessed in a TC10 Automated 
cell counter (Bio Rad, Berkeley, CA, USA).
Immunoblots and antibodies
Cells were suspended in lysis buffer (20 mM Tris-
HCl, pH 7.8, 50 mM NaCl, 5 mM EGTA, and 1% v/v 
Triton X-100) containing freshly added protease and 
phosphatase inhibitors (Roche). Lysates were clarified 
by centrifugation at 4°C, and protein concentration was 
determined by Bio-Rad protein assay.
To verify the protein contents of the BMSC-
ECM after alkaline detergent extraction, BMSC-ECM 
were scratched from culture plate and dissolved in 
buffer containing 100 mM Tris-HCl (pH 6.8), 200 mM 
dithiothreitol and 4% SDS. Samples were homogenized by 
pass through 27 g needle for at least 7 times, incubated on 
ice for 60 minutes, cleared by centrifugation and subjected 
to protein concentration assessment. Then 0.2% glycerol 
and 0.2% bromophenol blue (final concentration) were 
added and samples were heated at 95°C for 5 minutes.
The following antibodies are used: phosphor-
AKT Ser 473 and were from Cell Signalling. γ-H2AX, 
osteopontin, β-actin, MnSOD2, BCL-2, and BCL-xL were 
from Millipore. p27, p21, collagen 1, fibronectin, MCL-1, 
Gpx1/2, were from Santa Cruz Biotechnology.
Flow cytometry
ROS level (CM-H2DCFDA or CellROX™ Deep 
Red), Δψm (Mitotracker CMXRos), and Mitochondrial 
Ca2+ concentration (Rhod2-AM) were analyzed using a 
FACSCalibur flow cytometer (BD Bioscience, Oxford, 
UK). Intracellular GSH level were assessed in a LSR 
model II flow cytometry (BD Bioscience, Oxford, UK) 
with ThiolTracker™ Violet dye staining. The fluorescence 
dyes were from Invitrogen (Carlsbad, CA, USA), and data 
were analyzed using FlowJo software (FlowJo, Oregon, 
USA). Cell isolation by flow sorting was performed on a 
BD FACS Aria III (BD Bioscience).
Measurement of calcium concentration
The concentration of Calcium ions was measured 
by using Calcium Colorimetric Assay Kit (BioVision, 
Milpitas, CA, USA) and determined by recording the 
absorbance at 575 nm using a 96-well plate reader 
(FLUOstar Omega, BMG LABTECH, Germany).
Statistical analysis
Statistical analyses were performed using unpaired 
2-tailed Student’s t test for in vitro cell line data; non-
parametric Mann-Whitney test for in vivo and patients 
sample data. Statistical calculations were performed with 
GraphPad Prism software. P value < 0.05 was considered 
as significant. Data are expressed as means ± SEM. 
*p < 0.05, **p < 0.01, ***p < 0.001.
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